论文部分内容阅读
试水十来年的公立医院试点改革一路艰难地走来,为我国的医改积累了丰富的经验,得到了社会的高度认同,很大程度上缓解了人民群众“看病难、看病贵”的问题,但同时也面临着许多困难和挑战,有大量问题需要研究,其中药价虚高问题更是久治不愈的顽症。根据现行政策规定,药品价格管理主要分为三块,分别是政府控制、招标采购、医保议价。不过,受到多种因素的影响,药价虚高的问题并没有得到根本解决,在此背景下,药品“二次议价”的呼声越来越高。
The trial reform of public hospitals in the past ten years trying hard to find water has come a long way and has accumulated rich experience for the medical reform in our country. It has been highly recognized by the society and has greatly alleviated the people’s “difficult to see a doctor, expensive to see a doctor ” However, it also faces many difficulties and challenges. There are a large number of problems that need to be studied. Among them, the issue of the high price of medicines is a chronic problem. According to the current policy, drug price management is divided into three parts, namely government control, bidding and purchasing, and medical insurance bargaining. However, under the influence of many factors, the problem of the high price of medicines has not been fundamentally solved. In this context, the voices of drugs “secondary bargaining” are getting louder and louder.